X4 Pharmaceuticals, Inc (XFOR): Depreciation & Amortization
$1.28M
Year ended 2025-12-31
$1.67M
Trailing 12 months to 2026-06-30
+35.5%
3-year compound annual growth
+29.5%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.28M | +60.4% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $796.0K | +90.0% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $419.0K | -18.3% | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | $513.0K | +2.8% | 2025-03-26, From 2022-01-01 |
| 2021-12-31 | $499.0K | +42.2% | 2024-03-21, From 2021-01-01 |
| 2020-12-31 | $351.0K | +240.8% | 2023-03-21, From 2020-01-01 |
| 2019-12-31 | $103.0K | 0.0% | 2022-03-17, From 2019-01-01 |
| 2018-12-31 | $103.0K | +45.1% | 2021-03-19, From 2018-01-01 |
| 2017-12-31 | $71.0K | -75.1% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $285.0K | n/a | 2019-03-11, From 2016-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $1.28M | +60.4% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $1.96M | +7.8% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $1.47M | -56.9% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $8.31M | +12.7% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $3.96M | -22.4% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $4.62M | +14.3% |
| Alector, Inc. (ALEC) | 2025-12-31 | $5.72M | +5.8% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $1.38M | -16.0% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $287.0K | +394.8% |
Compare XFOR, CCCC, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗